Literature DB >> 12601478

[Clinical, pathological and molecular prognostic factors in colorectal carcinomas].

S E Baldus1.   

Abstract

Various aspects of the progression and prognosis of colorectal carcinoma have been investigated in numerous publications during recent years. An exact macroscopic and microscopic examination is still of basic importance but different factors of the molecular pathogenesis of colorectal carcinoma could be described by immunohistochemistry and molecular biology. Furthermore, they have been evaluated regarding their importance for the course of disease and prognosis and in particular, the different pathways of carcinogenesis and microsatellite instability were included. The detection of micrometastasis was investigated applying mostly molecular genetic methods. Numerous oncogenes, tumor suppressor genes and regulators of the cell cycle, markers of proliferation and apoptosis, cell adhesion antigens and angiogenetic factors were characterized with regard to their prognostic potential. In the future, so-called response predictors will presumably gain a certain relevance in the context of neoadjuvant (radiotherapy) chemotherapy. The present review summarizes these results and discusses the future clinical relevance.

Entities:  

Mesh:

Year:  2003        PMID: 12601478     DOI: 10.1007/s00292-002-0592-7

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  158 in total

Review 1.  Pathology report in colon cancer: what is prognostically important?

Authors:  C C Compton
Journal:  Dig Dis       Date:  1999       Impact factor: 2.404

2.  p21WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations.

Authors:  G Viale; C Pellegrini; G Mazzarol; P Maisonneuve; M L Silverman; S Bosari
Journal:  J Pathol       Date:  1999-02       Impact factor: 7.996

3.  ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

Authors:  Y Shirota; J Stoehlmacher; J Brabender; Y P Xiong; H Uetake; K D Danenberg; S Groshen; D D Tsao-Wei; P V Danenberg; H J Lenz
Journal:  J Clin Oncol       Date:  2001-12-01       Impact factor: 44.544

4.  Prognostic significance of p53 mutations in colon cancer at the population level.

Authors:  Wade S Samowitz; Karen Curtin; Khe-ni Ma; Sandra Edwards; Donna Schaffer; Mark F Leppert; Martha L Slattery
Journal:  Int J Cancer       Date:  2002-06-01       Impact factor: 7.396

Review 5.  The HER-2/neu oncogene in tumors of the gastrointestinal tract.

Authors:  J S Ross; B J McKenna
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

6.  Microsatellite instability and the role of hMSH2 in sporadic colorectalcancer.

Authors:  V J Bubb; L J Curtis; C Cunningham; M G Dunlop; A D Carothers; R G Morris; S White; C C Bird; A H Wyllie
Journal:  Oncogene       Date:  1996-06-20       Impact factor: 9.867

7.  Clinicopathological characteristics of mucinous carcinoma of the colon and rectum.

Authors:  T Nozoe; H Anai; S Nasu; K Sugimachi
Journal:  J Surg Oncol       Date:  2000-10       Impact factor: 3.454

8.  Clinical and pathologic prognostic indicators in colorectal cancer. A population-based study.

Authors:  M Ponz de Leon; M Sant; A Micheli; C Sacchetti; C Di Gregorio; R Fante; G Zanghieri; G Melotti; G Gatta
Journal:  Cancer       Date:  1992-02-01       Impact factor: 6.860

Review 9.  Beta-catenin and the morphogenesis of colorectal cancer.

Authors:  Thomas Brabletz; Andreas Jung; Thomas Kirchner
Journal:  Virchows Arch       Date:  2002-04-27       Impact factor: 4.064

Review 10.  [Molecular cancer disposition diagnosis exemplified by colorectal carcinoma. What is the contribution of pathology?].

Authors:  J Rüschoff; W Dietmaier; T Bocker; S Wallinger; F Kullmann; A Beham; F Hofstädter
Journal:  Pathologe       Date:  1998-07       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.